Younger male teenager with visible acne smiling confidently at camera.

Potent doses for rapid results

Not an actual patient.

Discover a visible difference as early as Week 21,2*

PATIENT:
1
2
3
4
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.
A series of photos showing patient progress using TWYNEO cream at Week 0, 2, and 12.

Success

Male

Failure

Female

Success

Male

Failure

Female

Study SGT-65-04SGT-65-05: double-blind, randomized, vehicle-controlled safety and efficacy 12-week study of tretinoin, (0.1%) and benzoyl peroxide, (3%) vs vehicle cream.3

SEE FULL STUDY DESIGN

Dive into the data

SIGNIFICANT REDUCTION IN INFLAMMATORY ACNE LESIONS1,3:

27% AT WEEK 2†‡

∼66% AT WEEK 12‡

Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12.
REDUCTION IN INFLAMMATORY ACNE LESIONS2,3:

24% AT WEEK 2†‡

∼58% AT WEEK 12‡

Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12.
PIVOTAL STUDY 1
SIGNIFICANT REDUCTION IN NONINFLAMMATORY ACNE LESIONS1,3:

25% AT WEEK 2†‡

∼62% AT WEEK 12‡

Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12.
SIGNIFICANT REDUCTION IN NONINFLAMMATORY ACNE LESIONS2,3:

22% AT WEEK 2‡

∼55% AT WEEK 12‡

Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12.
PIVOTAL STUDY 1
∼3X MORE PATIENTS WERE CLEAR OR ALMOST CLEAR AT WEEK 121,3§||#
Bar charts showing percent of patients with clear or almost clear skin at Week 12. Bar charts showing percent of patients with clear or almost clear skin at Week 12.
MORE PATIENTS WERE CLEAR OR ALMOST CLEAR2,3§¶#
Bar charts showing percent of patients with clear or almost clear skin at Week 12. Bar charts showing percent of patients with clear or almost clear skin at Week 12.
PIVOTAL STUDY 1
*

Noninflammatory lesion reduction at Week 2.1,2

†

Multiple imputation (MCMC) used to impute missing values. Percent at Week 2 represents values obtained from averaging the summary statistics generated from each imputed data set.1,2

‡

Percent change analysis was conducted separately from analysis of absolute change.1,2

§

IGA (Investigator Global Assessment) success was defined as an IGA score of 0 (clear) or 1 (almost clear) and at least a 2-grade improvement (decrease) from baseline at Week 12.3

||

Above results based on MI analysis. In Study SGT-65-04, 38.5% of subjects treated with E-BPO/T achieved IGA success vs 11.5% for vehicle (P<0.001).1

Above results based on MI analysis. In Study SGT-65-05, 25.4% of subjects treated with E-BPO/T achieved IGA success vs 14.7% for vehicle (P=0.017).2

#

Multiple imputation (MCMC) used to impute missing values.1,2

References: 1. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-04; May 28, 2020. 2. Galderma Laboratories, L.P.; data on file. Clinical Study Report SGT-65-05; June 5, 2020. 3. TWYNEO (tretinoin and benzoyl peroxide) cream, 0.1%/3% [Prescribing Information]. Fort Worth, TX: Galderma Laboratories, L.P.; July 2021.

× Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12.
× Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in inflammatory lesions, highlighting Weeks 2 and 12.
× Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12.
× Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12. Line graphs showing reduction in noninflammatory lesions, highlighting Weeks 2 and 12.
× Bar charts showing percent of patients with clear or almost clear skin at Week 12. Bar charts showing percent of patients with clear or almost clear skin at Week 12.
× Bar charts showing percent of patients with clear or almost clear skin at Week 12. Bar charts showing percent of patients with clear or almost clear skin at Week 12.